Imagine this: a drug, an old friend in the medical world, is about to show us a new trick. It's a bold statement, but one that might just change the game for patients with atrial fibrillation (AF) and overweight or obesity. The META-AF trial has uncovered a potential game-changer, and it's got everyone talking.
In a recent presentation at the American Heart Association's 2025 Scientific Sessions, researchers revealed that the diabetes drug metformin could reduce the recurrence of atrial arrhythmia in patients with overweight and obesity, even if they're not diabetic. But here's where it gets controversial: the benefits aren't solely attributed to weight loss or glycemic control, which is typically what we'd expect from metformin.
Dr. Amrish Deshmukh, the lead investigator, shared some intriguing speculations. Beyond the small weight loss, metformin seems to have direct metabolic effects on cardiac myocytes, potentially preventing AF. This is a big deal, especially considering the well-established link between diabetes and AF, and the increased risk posed by elevated body mass index (BMI).
The META-AF trial enrolled 117 patients with AF and overweight or obesity, randomizing them to receive either usual care or metformin up to 6 weeks before their catheter ablation procedure. The results? Atrial arrhythmia recurrence was halved in the metformin group compared to usual care, and freedom from recurrence was significantly higher. Additionally, the AF burden was lower with metformin.
But here's the part most people miss: the study didn't assess long-term metformin use, and it was open-label, meaning both patients and researchers knew which treatment was being given. So, while the initial findings are exciting, more research is needed to fully understand the legacy effect of metformin beyond one year.
Dr. Gregory G. Schwartz, the discussant, posed an intriguing question: "Can an old dog learn new tricks?" In the case of metformin, it seems the answer is a resounding yes. With its long history, dating back to the 17th century as an herbal remedy, metformin has proven its worth time and again. Now, it might just have a new role as an anti-arrhythmic agent.
So, what do you think? Is metformin ready to step into this new role? The findings certainly suggest further exploration is warranted. Let's continue the conversation and explore the potential of this old drug with new tricks.
